Thrombosis in conversation

Episode 14: Wearables: Are they ready for the prime time?

Dr Jackson and Dr Barnes take a closer look at the hot topic of wearable devices in AF detection – their potential benefits and limitations – and how physicians can best discuss wearables with their patients.

Episode 13: Patient case study: Older and frail adult with AF at high risk of bleeding

Dr Larry Jackson and Dr Barnes consider how best to tackle a patient case study with a focus on optimal management of AF in older patients at high risk of bleeding.

Episode 12: Unravelling AF and comorbidities

Dr Barnes and Dr Frederik Verbrugge take a closer look at the management of stroke risk in people with AF and comorbid conditions.

Episode 11: Real-world evidence: Anticoagulation strategies for CAT

“There’s no doubt that pharmacological prophylaxis is under used.” Dr Carrier and Dr Barnes discuss the real-world evidence underpinning strategy for the management of CAT.

Episode 10: Cancer heterogeneity and CAT

Dr Marc Carrier and Dr Barnes discuss the challenges posed by cancer heterogeneity when managing CAT.

Episode 9: Unmet medical needs in AF management

Dr Proietti and Professor Lip highlight unmet needs in AF management for stroke prevention and their prevalence among people with AF.

Episode 8: Real-world evidence for managing AF in stroke prevention

Can real-world evidence improve treatment selection and individualised care for AF in stroke prevention? Dr Proietti and Professor Lip discuss.

Episode 7: AF screening and detection technologies in stroke prevention

“Wearable technologies for stroke prevention are an exciting trend in the field” Dr Proietti and Professor Lip examine the benefits and disadvantages of wearable technologies for AF screening and detection in stroke prevention.

Episode 6: Treatments and guideline recommendations for managing CAT

Dr Rajasekhar and Dr Barnes consider treatment selection for CAT, highlighting the role of warfarin, and discuss optimal treatment length and the use of IVC filters according to current guidelines.

Episode 5: Assessment and guideline recommendations for recurrent VTE in patients without cancer

“Why did a patient get their blood clot in the first place, and how does that influence our decisions?” Dr Barnes is joined by Dr Anita Rajasekhar for a discussion of the causes and risk factors of VTE in people without cancer, and the relationship of risk and cause with treatment selection. With reference to clinical guidance, Dr Rajasekhar talks about diagnosis of recurrent VTE in the clinical setting and the importance of patient preference.